Every 424B that VAXART INC (VXRT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VXRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VXRT filings page.
Vaxart, Inc. registers up to 32,914,599 shares of common stock for resale by Lincoln Park Capital Fund, LLC, comprising up to 32,467,532 Purchase Shares and 447,067 Commitment Shares. The company is not selling shares here and will receive no proceeds from Lincoln Park’s resales; however, Vaxart may receive up to $25 million in gross proceeds from sales of Purchase Shares to Lincoln Park under a Purchase Agreement that provides committed equity financing. The prospectus states 241,973,011 shares outstanding prior to this registration and 274,440,543 shares outstanding after (reflecting potential issuance of Purchase Shares), and discloses recent market data of $0.74 per share (closing OTC price on May 7, 2026). The resale program permits Lincoln Park to sell registered shares in various ways and at varying prices; the Purchase Agreement contains formulas and timing mechanics governing purchases by Lincoln Park and limits on resale methods are described in the Plan of Distribution.
Vaxart, Inc. has filed a prospectus supplement to sell up to $49,772,479 of common stock through an at‑the‑market (ATM) offering under a Sales Agreement with Citizens JMP Securities, LLC and B. Riley Securities, Inc. The Sales Agents may sell shares from time to time on Nasdaq, other trading venues, or in privately negotiated transactions, and are entitled to commissions up to 3% of gross sales.
The prospectus supplement bases the offering on 241,414,053 shares outstanding as of April 10, 2026 and illustrates a pro forma share count of up to 320,417,987 shares assuming sales at $0.63 per share. Net proceeds will equal gross proceeds less commissions and offering expenses; proceeds are intended for general corporate purposes including working capital, operating expenses and capital expenditures. The filing discloses a going‑concern funding need and states cash, cash equivalents and investments of $63.8 million as of December 31, 2025.
Vaxart, Inc. is offering and selling 11,111,111 shares of common stock at $0.45 per share in a privately negotiated transaction with Dynavax Technologies Corporation.
The company estimates net proceeds of approximately $5 million, to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. No underwriters or placement agents are involved. Delivery of shares is expected on or about November 6, 2025. Shares outstanding were 228,957,259 as of September 30, 2025, and are expected to be 240,069,844 immediately after the offering. Vaxart’s stock trades on the OTCQX under VXRT; the last reported price on November 3, 2025 was $0.33 per share.